Clinical TrialsConnect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Connect Biopharma Joins AAD Wave with Strong Phase 3 Rademikibart Data in A... Read Post »
Clinical TrialsBeyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Beyond Adults: Idorsia’s Daridorexant Shows Promise in Pediatric Insomnia Read Post »
Health Tidings Mergers & AcquisitionsAfter NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico After NVIDIA, Lilly Signs New AI Drug Discovery Deal with Insilico Read Post »
Clinical TrialsBMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... BMS Reports Stable Cobenfy Switch Data and Positive Phase 3 Camzyos Results... Read Post »
Health TidingsFDA Clears IND for Sialic Acid Prodrug UX016 in GNEM FDA Clears IND for Sialic Acid Prodrug UX016 in GNEM Read Post »
Health TidingsAmgen’s Repatha Lowers First CV Risk in High-Risk Patients Amgen’s Repatha Lowers First CV Risk in High-Risk Patients Read Post »
New Drug ApprovalBiogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Biogen’s High-Dose Spinraza Approved by FDA Backed by DEVOTE Data Read Post »
Clinical TrialsBiogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Biogen’s Litifilimab Shows Phase 2 AMETHYST Success in Cutaneous Lupus Read Post »
ResearchCorcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Corcept MOMENTUM Study Finds 27% Hypercortisolism in Resistant Hypertension Read Post »
Health TidingsSanofi’s Sarclisa SC Gets CHMP Nod with OBI Option Sanofi’s Sarclisa SC Gets CHMP Nod with OBI Option Read Post »
Health TidingsAfter FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in Psoria... After FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in Psoria... Read Post »
Health TidingsPriovant’s Brepocitinib Gains Priority Review After Phase 3 Success Priovant’s Brepocitinib Gains Priority Review After Phase 3 Success Read Post »
Health TidingsNovartis’ Fabhalta Cuts Kidney Function Decline by 50% in Phase 3 Novartis’ Fabhalta Cuts Kidney Function Decline by 50% in Phase 3 Read Post »
Health TidingsBIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control i... BIMZELX Shows Durable Remission in Psoriasis and Sustained 3-Year Control i... Read Post »
Clinical TrialsTakeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Results ... Read Post »
Clinical TrialsIncyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Incyte Reports Strong 1-Year Data for Povorcitinib in Hidradenitis Suppurat... Read Post »
Clinical TrialsTaltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Taltz+Zepbound Outperforms Taltz Alone in PsA Patients with Obesity Read Post »
Clinical TrialsLilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Lilly’s EBGLYSS Reinforces Long-Term Disease Control in Atopic Dermatitis Read Post »
Clinical TrialsSanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Sanofi Reports Phase 3 Success for Amlitelimab in Atopic Dermatitis Read Post »
Health TidingsOrganon Highlights Week 1 Improvements with VTAMA in Atopic Dermatitis Organon Highlights Week 1 Improvements with VTAMA in Atopic Dermatitis Read Post »
Health TidingsFDA Clears Lantern–Starlight STAR-001 Study in Pediatric Brain Cancer FDA Clears Lantern–Starlight STAR-001 Study in Pediatric Brain Cancer Read Post »
Clinical TrialsLenvima, Welireg Moves Closer to Approval with Japan Submission Lenvima, Welireg Moves Closer to Approval with Japan Submission Read Post »
New Drug ApprovalCHMP Recommends Five New Medicines for EU Approval in March 2026 CHMP Recommends Five New Medicines for EU Approval in March 2026 Read Post »
Health TidingsOtsuka Seeks Japan Approval for First-Line Use of Iclusig in Ph+ ALL Otsuka Seeks Japan Approval for First-Line Use of Iclusig in Ph+ ALL Read Post »
Clinical TrialsAstraZeneca Reports Positive Phase III Data for Tozorakimab in COPD AstraZeneca Reports Positive Phase III Data for Tozorakimab in COPD Read Post »
Health TidingsGSK’s Bepirovirsen Accepted by EMA for Review in Chronic Hepatitis B GSK’s Bepirovirsen Accepted by EMA for Review in Chronic Hepatitis B Read Post »
Mergers & AcquisitionsNovartis to Acquire Excellergy for Up to $2 Billion, Adds Next-Generation A... Novartis to Acquire Excellergy for Up to $2 Billion, Adds Next-Generation A... Read Post »
New Drug ApprovalChina Approves ENHERTU as First HER2 ADC for Neoadjuvant Breast Cancer China Approves ENHERTU as First HER2 ADC for Neoadjuvant Breast Cancer Read Post »
Mergers & AcquisitionsOtsuka to Acquire Transcend Therapeutics in Up to $1.2B Deal to Advance PTS... Otsuka to Acquire Transcend Therapeutics in Up to $1.2B Deal to Advance PTS... Read Post »
Health Tidings Mergers & AcquisitionsBiogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Bio... Biogen Signs Deal with Alteogen to Develop Subcutaneous Versions of Two Bio... Read Post »
Clinical TrialsWave’s RNA Therapy WVE-007 Shows Early Fat-Loss Signal in INLIGHT Trial Wave’s RNA Therapy WVE-007 Shows Early Fat-Loss Signal in INLIGHT Trial Read Post »
GenericsNovo Nordisk Sues Dr. Reddy’s Over “Olymviq” Name, Says It Too Closel... Novo Nordisk Sues Dr. Reddy’s Over “Olymviq” Name, Says It Too Closel... Read Post »
New Drug ApprovalNovo Nordisk Wins FDA Approval for Once-Weekly Basal Insulin Awiqli Novo Nordisk Wins FDA Approval for Once-Weekly Basal Insulin Awiqli Read Post »
New Drug ApprovalFDA Grants Accelerated Approval to Rocket’s Kresladi Gene Therapy for... FDA Grants Accelerated Approval to Rocket’s Kresladi Gene Therapy for... Read Post »
Health TidingsOno Submits Ripretinib for Approval in Japan to Treat Advanced Gastrointest... Ono Submits Ripretinib for Approval in Japan to Treat Advanced Gastrointest... Read Post »
Medical DevicesNovocure Reports Encouraging Phase 2 Data for TTFields in Pancreatic Cancer Novocure Reports Encouraging Phase 2 Data for TTFields in Pancreatic Cancer Read Post »
Clinical TrialsEncoded Aligns with FDA on Pivotal ENDEAVOR Trial Design for ETX101 in Drav... Encoded Aligns with FDA on Pivotal ENDEAVOR Trial Design for ETX101 in Drav... Read Post »
Mergers & AcquisitionsJanux Targets 2026 TRACTr Updates, Announces BMS Collaboration Janux Targets 2026 TRACTr Updates, Announces BMS Collaboration Read Post »
ManufacturingIonis Cuts TRYNGOLZA Price Ahead of Potential sHTG Approval Ionis Cuts TRYNGOLZA Price Ahead of Potential sHTG Approval Read Post »
Clinical TrialsCompass Updates COMP360 Pipeline, Targets FDA Filing in TRD Compass Updates COMP360 Pipeline, Targets FDA Filing in TRD Read Post »
New Drug ApprovalCorcept’s Relacorilant Combo Approved for Resistant Ovarian Cancer Corcept’s Relacorilant Combo Approved for Resistant Ovarian Cancer Read Post »
CRO Medical DevicesTerumo, Tata Elxsi Open Offshore Center for Cardiovascular Innovation Terumo, Tata Elxsi Open Offshore Center for Cardiovascular Innovation Read Post »
New Drug ApprovalFDA Clears Denali’s AVLAYAH, First Brain-Penetrant Therapy for Hunter... FDA Clears Denali’s AVLAYAH, First Brain-Penetrant Therapy for Hunter... Read Post »
Clinical TrialsInnovent Reports Positive Phase 3 Data for IBI302 in Wet AMD Innovent Reports Positive Phase 3 Data for IBI302 in Wet AMD Read Post »
Clinical TrialsSarepta Advances siRNA Pipeline with Early FSHD and DM1 Trial Data Sarepta Advances siRNA Pipeline with Early FSHD and DM1 Trial Data Read Post »
Health Tidings Mergers & AcquisitionsMerck to Buy Terns, Strengthening CML Pipeline with TERN-701 Merck to Buy Terns, Strengthening CML Pipeline with TERN-701 Read Post »
Clinical TrialsNovo Nordisk, TUL Report Positive UBT251 Phase 2 Results Novo Nordisk, TUL Report Positive UBT251 Phase 2 Results Read Post »
Health Tidings Mergers & AcquisitionsAlnylam, Viz.ai Partner to Advance AI Detection of ATTR-CM Alnylam, Viz.ai Partner to Advance AI Detection of ATTR-CM Read Post »
Clinical TrialsOcugen’s OCU410 Demonstrates 31% Lesion Reduction in Phase 2 GA Trial Ocugen’s OCU410 Demonstrates 31% Lesion Reduction in Phase 2 GA Trial Read Post »
Health TidingsFDA Warns ImmunityBio Over Misleading Promotion of Cancer Drug ANKTIVA FDA Warns ImmunityBio Over Misleading Promotion of Cancer Drug ANKTIVA Read Post »
